EUVIMEDEUVIMED entdecken
Open Access

Qualitative Examination of US and Israeli Adults’ Perceptions of IQOS Advertising Messages: Modified Exposure and Risk Statements, US FDA Endorsement, and Health Warnings

Carla J Berg iD, Hagai Levine, Cassidy R LoParco iD, Yuxian Cui, Amal Khayat iD, Zongshuan Duan iD, Lorien C Abroms, Yan Wang, Yael Bar-Zeev iD

Nicotine and Tobacco Research · 2025

DOI: 10.1093/ntr/ntae266 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nicotine and Tobacco Research, 2025. Verfasst von Carla J Berg und 8 weiteren Autor:innen. Beteiligte Einrichtung: Milken Institute School of Public Health, George Washington University, Washington, DC, USA. Hauptthemen laut MEDLINE: Advertising, Tobacco Products, Product Labeling. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, FIC NIH HHS, US National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

IQOS, a leading heated tobacco product, is advertised as less harmful than cigarettes and received US Food and Drug Administration (FDA) authorization for “reduced exposure” advertising claims. Perceptions of advertising messages, including reduced exposure/risk” claims, FDA endorsements, and health warning labels (HWLs), are understudied. Aims and Methods Qualitative interviews (N = 84) from US and Israeli adults (2022) examined perceptions of advertising messages, specifically: 1) scientific claims that switching completely from cigarettes to IQOS reduces 1a) chemical exposure and 1b) tobacco-related disease risk; 2) FDA endorsement of IQOS as a 2a) better choice for adult smokers and 2b) fundamentally different product (heat-not-burn); and 3) promoting IQOS as cigarette alternatives with a HWL pertaining to cigarettes.

Results

For half of the participants, referencing scientific studies or the FDA enhanced credibility; some believed this implied unbiased, rigorous research. Half were skeptical due to lack of research-related details. Half interpreted message 1 (switching) to mean any substitution could be beneficial; half interpreted it as complete substitution was necessary. Most did not perceive differences between message 1a (reduced exposure) versus 1b (reduced risk). Some believed message 2a (FDA endorsement, not targeting youth) demonstrated IQOS’ social responsibility. Some interpreted message 2b (fundamentally different product) as risk reduction; others perceived no difference. The majority paraphrased messages using the terms “safer,” “healthier,” or “less harmful.” For message 3 (a safer alternative), some did not think the HWL applied to IQOS; some believed it promoted IQOS.

Conclusions

Regulators and researchers must monitor harm-reduction advertising messaging and take actions to prevent consumer misinterpretations.

Implications

Philip Morris International’s IQOS received US Food and Drug Administration (FDA) authorization for “reduced exposure” advertising claims, which are often misinterpreted, and has exploited FDA authorization to promote IQOS globally. This qualitative study showed that most participants perceived no difference between reduced risk versus exposure messages in IQOS ads, half believed that references to scientific studies or FDA enhanced credibility, some believed certain messages demonstrated IQOS’ social responsibility, and some perceived warnings in IQOS ads to promote IQOS. Product ads using harm reduction messages must be monitored to inform efforts to prevent potentially harmful misinterpretations and mitigate negative population-level impacts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdvertisingTobacco ProductsProduct LabelingHumansUnited StatesUnited States Food and Drug AdministrationAdultFemaleMaleQualitative ResearchMiddle AgedIsraelYoung AdultPerception

Autor:innen und Institutionen

  • Milken Institute School of Public Health, George Washington University, Washington, DC, USA.
  • GW Cancer Center, George Washington University, Washington, DC, USA.
  • Braun School of Public Health and Community Medicine, Faculty of Medicine, Hebrew University of Jerusalem and Hadassah Medical Center, Jerusalem, Israel.
  • School of Public Health, Georgia State University, Atlanta, GA, USA.

ORCID-Profile: Carla J Berg, Cassidy R LoParco, Amal Khayat, Zongshuan Duan, Yael Bar-Zeev

Förderung

  • NCI NIH HHS
  • FIC NIH HHS
  • US National Cancer Institute
  • National Cancer Institute

Zitieren

APA

Berg, C. J., Levine, H., LoParco, C. R., Cui, Y., Khayat, A., Duan, Z., Abroms, L. C., Wang, Y., & Bar-Zeev, Y. (2025). Qualitative Examination of US and Israeli Adults’ Perceptions of IQOS Advertising Messages: Modified Exposure and Risk Statements, US FDA Endorsement, and Health Warnings. Nicotine and Tobacco Research. https://doi.org/10.1093/ntr/ntae266

Vancouver

Berg CJ, Levine H, LoParco CR, Cui Y, Khayat A, Duan Z, et al. Qualitative Examination of US and Israeli Adults’ Perceptions of IQOS Advertising Messages: Modified Exposure and Risk Statements, US FDA Endorsement, and Health Warnings. Nicotine and Tobacco Research. 2025. doi:10.1093/ntr/ntae266

BibTeX
@article{Berg2025,
  author = {Berg, Carla J and Levine, Hagai and LoParco, Cassidy R and Cui, Yuxian and Khayat, Amal and Duan, Zongshuan and Abroms, Lorien C and Wang, Yan and Bar-Zeev, Yael},
  title = {Qualitative Examination of US and Israeli Adults’ Perceptions of IQOS Advertising Messages: Modified Exposure and Risk Statements, US FDA Endorsement, and Health Warnings},
  journal = {Nicotine and Tobacco Research},
  year = {2025},
  doi = {10.1093/ntr/ntae266}
}
Kostenlos starten →